- Home
- SYTA vs REVB Comparison
SYTA vs REVB Comparison
Compare SYTA & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYTA
- REVB
- Stock Information
- Founded
- SYTA 1986
- REVB 2020
- Country
- SYTA Canada
- REVB United States
- Employees
- SYTA N/A
- REVB N/A
- Industry
- SYTA Telecommunications Equipment
- REVB Biotechnology: Pharmaceutical Preparations
- Sector
- SYTA Telecommunications
- REVB Health Care
- Exchange
- SYTA Nasdaq
- REVB Nasdaq
- Market Cap
- SYTA 3.1M
- REVB 2.8M
- IPO Year
- SYTA 2020
- REVB N/A
- Fundamental
- Price
- SYTA $1.21
- REVB $2.92
- Analyst Decision
- SYTA
- REVB
- Analyst Count
- SYTA 0
- REVB 0
- Target Price
- SYTA N/A
- REVB N/A
- AVG Volume (30 Days)
- SYTA 274.4K
- REVB 146.9K
- Earning Date
- SYTA 05-15-2025
- REVB 05-09-2025
- Dividend Yield
- SYTA N/A
- REVB N/A
- EPS Growth
- SYTA N/A
- REVB N/A
- EPS
- SYTA N/A
- REVB N/A
- Revenue
- SYTA $11,629,572.00
- REVB N/A
- Revenue This Year
- SYTA $14.02
- REVB N/A
- Revenue Next Year
- SYTA N/A
- REVB N/A
- P/E Ratio
- SYTA N/A
- REVB N/A
- Revenue Growth
- SYTA 41.25
- REVB N/A
- 52 Week Low
- SYTA $1.10
- REVB $2.36
- 52 Week High
- SYTA $885.60
- REVB $60.80
- Technical
- Relative Strength Index (RSI)
- SYTA 29.94
- REVB 45.77
- Support Level
- SYTA $1.15
- REVB $2.76
- Resistance Level
- SYTA $1.28
- REVB $3.62
- Average True Range (ATR)
- SYTA 0.15
- REVB 0.41
- MACD
- SYTA 0.01
- REVB 0.02
- Stochastic Oscillator
- SYTA 14.25
- REVB 34.12
About SYTA Siyata Mobile Inc.
Siyata Mobile Inc is engaged in the sale of vehicle mounted, cellular-based communications platforms over advanced 3G (Third generation) mobile networks and cellular booster systems. The Company develops, markets and sells a portfolio of rugged handheld Push-to-Talk over Cellular (PoC) smartphone devices. These rugged business-to-business (B2B) environments are focused on enterprise customers, first responders, construction workers, security guards, government agencies, utilities, transportation and waste management, amusement parks, and mobile workers in multiple industries. The company operates in USA, Canada, EMEA and Australia. It derives maximum revenue from USA.
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).